FDA approves new agent for multiple myeloma.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of the National Cancer Institute

• Publication date

  2015-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/jnci/djv165PMID 26032612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Capsaicin-Inspired Hydroxamate Hybrids as Selective HDAC6 Inhibitors with Antiproliferative Activity in Hematological Malignancies

  2026cites this paper
• Synthesis and cytotoxic evaluation of 2-aminobenzothiazole amide derivatives inspired by hydroxamate structural motifs

  2026cites this paper
• Clinical Efficacy and Mechanistic Insights of FDA-Approved HDAC Inhibitors in the Treatment of Lymphoma.

  2025cites this paper
• Recent advances in the synthesis and biological evaluation of hybrid compounds. Mini‐review: An account

  2025cites this paper
• In Silico Profiling of Histone Deacetylase 8 Inhibitory Activity: A Computational Analysis of Novel Dipeptide-Based Compounds Cross-Linked with Hydroxamic Acid

  2024cites this paper
• Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses.

  2023cites this paper
• Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases

  2022cites this paper
• Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience

  2022cites this paper
• Histone Deacetylase Inhibitors Restore Cancer Cell Sensitivity towards T Lymphocytes Mediated Cytotoxicity in Pancreatic Cancer

  2022cites this paper
• Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.

  2022cites this paper
• Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.

  2021cites this paper
• Epigenetics in acute myeloid leukemia

  2021cites this paper
• Targeting Post-Translational Modifications of the p73 Protein: A Promising Therapeutic Strategy for Tumors

  2021cites this paper
• Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: an emerging approach to overcome MSC-induced resistance.

  2020cites this paper
• Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative in silico study

  2020cites this paper
• Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study

  2020cites this paper
• Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation.

  2020cites this paper
• Fluid-electrolyte homeostasis requires histone deacetylase function

  2020cites this paper
• Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors

  2020cites this paper
• Design, Synthesis, and Cytotoxic Evaluation of Novel Lupane Triterpenoid Derived Hydroxamates

  2020cites this paper
• An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies

  2020cites this paper
• Synthesis and Biological Evaluation of a Depsipeptidic Histone Deacetylase Inhibitor via a Generalizable Approach Using an Optimized Latent Thioester Solid-Phase Linker.

  2020cites this paper
• Discriminations of active from inactive HDAC8 inhibitors Part II: Bayesian classification study to find molecular fingerprints

  2020cites this paper
• Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.

  2019cites this paper
• Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma

  2019cites this paper
• Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.

  2019cites this paper
• The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy

  2019cites this paper
• Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining

  2018cites this paper
• Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.

  2018cites this paper
• Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation.

  2018cites this paper
• HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.

  2018cites this paper
• Histone deacetylase inhibitors as a new anticancer option : How far can we go with expectations ?

  2018cites this paper
• Kinetically selective and potent inhibitors of HDAC8

  2018cites this paper
• PUBLISHED VERSION

  2018cites this paper
• Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery.

  2017cites this paper
• HDAC8 substrate selectivity is determined by long- and short-range interactions leading to enhanced reactivity for full-length histone substrates compared with peptides

  2017cites this paper
• Is dual inhibition of metalloenzymes HDAC‐8 and MMP‐2 a potential pharmacological target to combat hematological malignancies?

  2017cites this paper
• Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts

  2017cites this paper
• Understanding HDAC8-Catalyzed Deacetylation:From New Substrates to Diseases

  2017cites this paper
• ATF 3 repression of BCL-X L determines apoptotic sensitivity to HDAC inhibitors across tumour types

  2017cites this paper
• Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma?

  2017cites this paper
• Elevation of YAP promotes the epithelial‐mesenchymal transition and tumor aggressiveness in colorectal cancer

  2017cites this paper
• BRD4 inhibition for the treatment of pathological organ fibrosis

  2017cites this paper
• ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

  2017cites this paper
• Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma

  2016cites this paper
• The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy

  2016cites this paper
• A direct alkylation route to branched derivatives of suberoylanilide hydroxamic acid (SAHA), a potent non-selective inhibitor of histone deacetylases

  2016cites this paper
• Unlocking an HDAC Toolbox: Methods toward Understanding Isozyme-specific Activity.

  2016cites this paper
• Epigenetics in Acute Myeloid Leukemia

  2016cites this paper
• Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer

  2016cites this paper
• Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy

  2016cites this paper
• Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.

  2016cites this paper
• Inside HDACs with more selective HDAC inhibitors.

  2016cites this paper
• KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma.

  2016cites this paper
• Metal-dependent Deacetylases: Cancer and Epigenetic Regulators.

  2016cites this paper
• Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors

  2016cites this paper
• Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.

  2016cites this paper
• The Specificity and Regulation of Human Histone Deacetylase 8.

  2015cites this paper
• Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma

  2015cites this paper